Search
Patexia Research
Patent No. US 11213552
Issue Date Jan 4, 2022
Claim this patent
PDF Unavailable

Patent 11213552 - Method for treating an individual suffering from a chronic infectious disease and cancer > Claims

  • 1. A method for treating an individual suffering from a chronic infectious disease and who has cancer, comprising, using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas), selectively killing a pathogenic bacteria within the individual, said pathogenic bacteria selected from the group consisting of Staphylococcus aureus; Pseudomonas aeruginosa; Klebsiella; Streptoccocus; Salmonella; Shigella; Mycobacterium tuberculosis; Enterococcus; E coli; Clostridium; Neisseria gonnorrhoea; Acinetobacter baumannii; and Campylobacter, and enhancing the growth of a beneficial bacteria in the individual selected from the group consisting of Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, and Streptococcus bacteria; wherein said CRISPR Cas system comprises Cas3 and is delivered using a bacteriophage.
    • 2. The method as set forth in claim 1, wherein the cancer comprises colorectal or bladder cancer.
    • 3. The method as set forth in claim 1, further comprising administering to the individual an immune checkpoint inhibitor selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010.
    • 4. The method as set forth in claim 1, wherein using the CRISPR-Cas system, said pathogenic bacteria are killed while sparing other commensal bacteria.
    • 5. The method as set forth in claim 1, wherein the pathogenic bacteria comprises Klebsiella pneumoniae.
    • 6. The method as set forth in claim 1, wherein the CRISPR-Cas system is used to reduce virulence factors of the pathogenic bacteria.
  • 7. A method for treating an individual suffering from a chronic infectious disease and who has cancer, comprising, using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1), selectively killing pathogenic bacteria within the individual, said pathogenic bacteria comprising at least one of Staphylococcus aureus; Pseudomonas aeruginosa; Klebsiella; Streptoccocus; Salmonella; Shigella; Mycobacterium tuberculosis; Enterococcus; E coli; Clostridium; Neisseria gonnorrhoea; Acinetobacter baumannii; and Campylobacter; and administering to the individual an immune checkpoint inhibitor that specifically binds to an immune checkpoint protein selected from the group consisting of CTLA4, PD-1, PD-L1, PD-L2, A2AR, B7-H3, B7-H4, BTLA, KIR, LAG3, TIM-3 and VISTA.
    • 8. The method as set forth in claim 7, wherein the immune checkpoint inhibitor is selected from the group consisting of nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012 and STI-A1010.
    • 9. The method as set forth in claim 7, wherein the CRISPR-Cpf1 system is used to cut a gene expressed by the pathogenic bacteria.
    • 10. The method as set forth in claim 7, wherein the CRISPR-Cas or Cpf1 system is used to insert genes that have controllable elements such that the pathogenic bacteria cells are killed by triggering the expression of said inserted genes.
    • 11. The method as set forth in claim 7, wherein the CRISPR-Cas system or Cpf1 system is delivered by a bacteriophage.
    • 12. The method as set forth in claim 7, wherein said pathogenic bacteria comprises at least one of Enterobacter aerogenes, Acinetobacter baumannii, and Klebsiella pneumoniae.
    • 13. The method of claim 7, further comprising enhancing the growth of a beneficial bacteria in the individual selected from the group consisting of Akkermansia, Bacteroides, Bifidobacterium, Clostridium, Enterococcus, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Ruminococcus, Veillonella, Prevotella, and Streptococcus bacteria.
    • 14. The method as set forth in claim 7, wherein the CRISPR-Cas or Cpf1 system is used to cut a gene expressed by the pathogenic bacteria.
    • 15. The method as set forth in claim 7, wherein CRISPR-Cas or Cpf1 is used to insert antibacterial sensitivity into the genome of said pathogenic bacteria such that the pathogenic bacteria can selectively be killed.
    • 16. The method as set forth in claim 7, wherein CRISPR-Cas or Cpf1 is used to facilitate RNA-guided site-specific DNA cleavage to kill the pathogenic bacteria.
    • 17. The method as set forth in claim 7, wherein using CRISPR-Cas systems, said pathogenic bacteria are killed while sparing other commensal bacteria.
    • 18. The method as set forth in claim 7, wherein using one of a CRISPR-Cas or Cpf1 system, said pathogenic bacteria are modified to reduce virulence factors of said pathogenic bacteria.
  • 19. A method for treating an individual suffering from a chronic infectious disease and cancer, comprising, using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system from Prevotella and Francisella 1 (Cpf1), selectively killing a pathogenic bacteria within the individual, said pathogenic bacteria selected from the group consisting of: Staphylococcus aureus; Pseudomonas aeruginosa; Klebsiella; Streptoccocus; Salmonella; Shigella; Mycobacterium tuberculosis; Enterococcus; E coli; Clostridium; Neisseria gonnorrhoea; Acinetobacter baumannii; and Campylobacter, wherein the CRISPR-Cpf1 system is used to cut a gene expressed by the pathogenic bacteria;wherein the CRISPR-Cpf1 system is used to facilitate RNA-guided site-specific DNA cleavage to kill the pathogenic bacteria;wherein using the CRISPR-Cpf1 system said pathogenic bacteria are killed while sparing other commensal bacteria; andwherein the CRISPR-Cpf1 system is delivered to the pathogenic bacteria using a bacteriophage.
    • 20. The method as set forth in claim 19, wherein the CRISPR-Cpf1 system is used to insert genes that have controllable elements such that the pathogenic bacteria cells are killed by triggering the expression of said inserted genes.
Menu